Supernus Pharmaceuticals Inc（SUPN）の財務SUPNSupernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. (SUPN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Net product sales-Qelbree, accounting for 40.7% of total sales, equivalent to $89.24M. Other significant revenue streams include Net product sales - GOCOVRI and Collaboration revenue. Understanding this composition is critical for investors evaluating how SUPN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Supernus Pharmaceuticals, Inc. maintains a gross margin of 73.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.39%, while the net margin is -26.65%. These profitability ratios, combined with a Return on Equity (ROE) of -10.49%, provide a clear picture of how effectively SUPN converts its operational activities into shareholder value.

In the context of the broader market, SUPN competes directly with industry leaders such as HRMY and VRDN. With a market capitalization of $2.32B, it holds a significant position in the sector. When comparing efficiency, SUPN's gross margin of 73.07% stands against HRMY's 75.81% and VRDN's 100.00%. Such benchmarking helps identify whether Supernus Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Supernus reported a 32% year-over-year revenue increase to over $219 million in Q2 2026, but faced a significant net loss of over $58 million, contrasting sharply with a net income of $22.5 million in Q2 2025. The gross margin has also decreased to 73.07% in Q2 2026 from 79.65% in Q4 2024, indicating rising cost pressures.